Biohaven Pharmaceutical Holding Net Income 2016-2021 | BHVN

Biohaven Pharmaceutical Holding annual/quarterly net income history and growth rate from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Biohaven Pharmaceutical Holding net income for the quarter ending September 30, 2021 was $-0.172B, a 11.97% decline year-over-year.
  • Biohaven Pharmaceutical Holding net income for the twelve months ending September 30, 2021 was $-0.865B, a 23.89% increase year-over-year.
  • Biohaven Pharmaceutical Holding annual net income for 2020 was $-0.767B, a 45.01% increase from 2019.
  • Biohaven Pharmaceutical Holding annual net income for 2019 was $-0.529B, a 119.49% increase from 2018.
  • Biohaven Pharmaceutical Holding annual net income for 2018 was $-0.241B, a 73.08% increase from 2017.
Biohaven Pharmaceutical Holding Annual Net Income
(Millions of US $)
2020 $-767
2019 $-529
2018 $-241
2017 $-139
2016 $-64
2015 $-10
Biohaven Pharmaceutical Holding Quarterly Net Income
(Millions of US $)
2021-09-30 $-172
2021-06-30 $-211
2021-03-31 $-265
2020-12-31 $-218
2020-09-30 $-195
2020-06-30 $-181
2020-03-31 $-173
2019-12-31 $-149
2019-09-30 $-106
2019-06-30 $-211
2019-03-31 $-62
2018-12-31 $-55
2018-09-30 $-61
2018-06-30 $-39
2018-03-31 $-85
2017-12-31 $-27
2017-09-30 $-43
2017-06-30 $-46
2017-03-31 $-23
2016-12-31 $-26
2016-09-30 $-28
2016-06-30 $-7
2016-03-31 $-3
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $7.159B $0.064B
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $122.991B 7.77
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.439B 21.07
Arcus Biosciences (RCUS) United States $3.161B 0.00
Emergent Biosolutions (EBS) United States $2.298B 8.26
ADC Therapeutics SA (ADCT) Switzerland $1.545B 0.00
Myovant Sciences (MYOV) United Kingdom $1.443B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.348B 0.00
SQZ Biotechnologies (SQZ) United States $0.329B 0.00
Enzo Biochem (ENZ) United States $0.163B 16.00